Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anders Bugge

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|September 10, 2010
[Molecular imaging]Audun Elnaes Berstad, Hanne Solheim, Anders Bugge
The Annals of Thoracic Surgery|March 28, 2016
Survival After Surgical Resection for Lung Cancer in Patients With Chronic Obstructive Pulmonary DiseaseAnders Bugge, May Brit Lund, Cathrine Brunborg, et al.
Acta Oncologica (Stockholm, Sweden)|November 17, 2016
Gender-specific survival after surgical resection for early stage non-small cell lung cancerAnders Bugge, Johny Kongerud, Cathrine Brunborg, et al.
The Lancet. Oncology|May 2, 2016
Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trialJohan F Vansteenkiste, Byoung Chul Cho, Tonu Vanakesa, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|September 10, 2010
[Molecular imaging]Audun Elnaes Berstad, Hanne Solheim, Anders Bugge
The Annals of Thoracic Surgery|March 28, 2016
Survival After Surgical Resection for Lung Cancer in Patients With Chronic Obstructive Pulmonary DiseaseAnders Bugge, May Brit Lund, Cathrine Brunborg, et al.
Acta Oncologica (Stockholm, Sweden)|November 17, 2016
Gender-specific survival after surgical resection for early stage non-small cell lung cancerAnders Bugge, Johny Kongerud, Cathrine Brunborg, et al.
The Lancet. Oncology|May 2, 2016
Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trialJohan F Vansteenkiste, Byoung Chul Cho, Tonu Vanakesa, et al.
Pageof 1